Cancer Drug Discovery and Development Endoproteases as Drug Targets Safety Assessment of Cancer Therapeutics Molecular pharmacology Matrix metalloproteinase

Cross, J.M., Blower, T.R., Gallagher, N., Gill, J.H., Rockley, K.L. & Walton, J.W. (2016). Anticancer RuII and RhIII Piano-Stool Complexes that are Histone Deacetylase Inhibitors. ChemPlusChem 81. Jamie, K., Bows, H. & Gill, J. (2016). Integration of pharmacogenetic principles as a core thread in the undergraduate pharmacy curriculum. Pharmacy Education 16(1): 64-66. Cross, J.M., Gallagher, N., Gill, J.H., Jain, M., McNeillis, A.W., Rockley, K.L., Tscherny, F.H., Wirszycz, N.J., Yufit, D.S. & Walton, J.W. (2016). Pyridylphosphinate Metal Complexes: Synthesis, Structural Characterisation and Biological Activity. Dalton Transactions 45(32): 12807-12813. Ansari, C., Tikhomirov, G.A., Hong, S.H., Falconer, R.A., Loadman, P.M., Gill, J.H., Castaneda, R., Hazard, F.K., Tong, L., Lenkov, O.D., Felsher, D.W., Rao, J. & Daldrup-Link, H.E. (2014). Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy. Small 10(3): 566-575. Gill, J.H., Loadman, P.M., Shnyder, S.D., Cooper, P., Atkinson, J.M., Ribeiro Morais, G., Patterson, L.H. & Falconer, R.A. (2014). The Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity. Molecular Pharmaceutics 11(4): 1294-1300. Sutherland, M, Gill, J.H, Loadman, P.M, Laye, J.P, Sheldrake, H.M, Illingworth, N.A, Alandas, M.N, Cooper, P.A, Searcey, M, Pors, K, Shnyder, S.D & Patterson, L.H (2013). Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Molecular Cancer Therapeutics 12(1): 27-37. O'Farrell, AC, Shnyder, SD, Marston, G, Colletta, L & Gill, JH (2013). Non-invasive molecular imaging for preclinical cancer therapeutic development. British Journal of Pharmacology 169(4): 719-735. Boissinot, M, Inman, M, Hempshall, A, James, S.R, Gill J.H, Selby, P, Bowen, D.T, Grigg, R.E & Cockerill, P.N (2012). Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192. Leukemia Research 36(10): 1304-1310. Atkinson, J.M, Falconer, R.A, Edwards, D.R., Pennington, C.J., Siller, C.S., Shnyder, S.D., Bibby, M.C., Patterson, L.H, Loadman, P.M & Gill, J.H (2010). Development of a novel tumor-targeted vascular disrupting agent activated by Membrane-Type Matrix Metalloproteinases. Cancer Research 70(17): 6902-6912. Mardaryev, A.N, Ahmed, M.I, Vlahov, N.V, Fessing, M.Y, Gill, J.H, Sharov, A.A & Botchkareva, N.V (2010). Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle. FASEB Journal 24(10): 3869-3881. Krippner-Heidenreich, A, Grunwald, I, Zimmermann, G, Kühnle, M, Gerspach, J, Sterns, T, Shnyder, S, Gill, J.H, M?nnel, D, Pfizenmaier, K & Scheurich, P (2008). Single chain TNF, a TNF derivative with enhanced stability and antitumoral activity. Journal of Immunology 180(12): 8176-8183. Shnyder, S.D, Cooper, P.A, Millington, N.J, Gill, J.H & Bibby, M.C (2008). Sodium Pancratistatin 3,4-O-Cyclic Phosphate, a water soluble synthetic derivative of Pancratistatin, is highly effective in a human colon tumour model. Journal of Natural Products 71(3): 321-324. Atkinson, J.M, Siller, C.S & Gill, J.H (2008). Tumour endoproteases: the cutting edge of cancer drug delivery?. British Journal of Pharmacology 153(7): 1344-1352. Behrens, D, Gill, J.H & Fichtner, I (2007). Loss of tumourigenicity of stably ERβ-transfected MCF-7 breast cancer cells. Molecular and Cellular Endocrinology 274(1-2): 19-29. Atkinson, J.M, Pennington, C.J, Martin, S.W, Anikin, V.A, Mearns, A.J, Loadman, P.M, Edwards, D.R & Gill, J.H (2007). Membrane Type Matrix Metalloproteinases (MMPs) Show Differential Expression in Non-small Cell Lung Cancer (NSCLC) Compared to Normal Lung: Correlation of MMP-14 mRNA Expression and Proteolytic Activity. European Journal of Cancer 43(11): 1764-1771. Seargent, J.M, Loadman, P.M, Martin, S.W, Naylor, B, Bibby, M.C & Gill, J.H (2005). Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology 65(4): 815-820. Fichtner, I, Slisow, W, Gill, J.H, Becker, M, Elbe, B, Hillebrand, T & Bibby, M.C (2004). Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. European Journal of Cancer 40(2): 298-307. Seargent, J.M, Yates, E.A & Gill, J.H (2004). GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. British Journal of Pharmacology 143(8): 933-937. Basu, S, Brown, J.E, Flannigan, G.M, Gill, J.H, Loadman, P.M, Martin, S.W, Seargent, J.M, Shah, T, Puri, R & Phillips, R.M (2004). Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. International Journal of Cancer 109(5): 703-709. Gill, J.H, Kirwan, I.G, Seargent, J.M, Martin, S.W, Tijani, S, Anikin, V.A, Mearns, A.J, Bibby M.C, Anthoney, A & Loadman, P.M (2004). MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 6(6): 777-785.